Navigation Links
SPRI Clinical Trials Now Enrolling Patients for Study of New Treatment for Depression

Patient Recruitment Starting Now -- For More Information, Call 888-345-7774

or Visit Our Website at

NEW YORK, Oct. 15 /PRNewswire/ -- SPRI Clinical Trials announced today that it is now screening patients for enrollment in the parAGOn Clinical Trial Program, which will start with two Phase III studies to evaluate the efficacy, safety and tolerability of agomelatine, a novel, investigational, once-daily medication for the treatment of Major Depressive Disorder (MDD). The 8-week, randomized, placebo-controlled studies are sponsored by Novartis Pharmaceuticals Corporation, and each of the two Phase III studies will include 490 patients from approximately 50 centers.

This investigational new drug targets both melatonin receptors and serotonin (5-HT2c) receptors.

The parAGOn Clinical Trial Program is open to patients between the ages of 18 and 70 who are experiencing MDD and meet other eligibility criteria. Eligible patients will be equally randomized to receive either treatment with agomelatine 25 mg, agomelatine 50 mg or placebo once daily for 8 weeks. Patients who complete the eight-week double-blind treatment phase may also participate in a 52-week open-label extension of the study.

MDD is the most common mood disorder, affecting approximately 15 million American adults, according to the National Alliance on Mental Illness. Common symptoms include: depressed mood, loss of interest in daily activities, poor concentration, weight loss (or gain), decrease of appetite, sleep disturbance, feelings of worthlessness and /or of guilt, and suicidal ideation. Episodes of depression may be chronic and recurrent, according to the National Institute of Mental Health.

Contact Dr. Nick Vatakis at 888-345-7774 for more information about the ParAGOn Clinical Trial Program.

SOURCE SPRI Clinical Trials
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
Breaking Medicine News(10 mins):